biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Feb 26, 2016 2:52pm

209 Views

Post# 24599727

RE:RE:RE:RE:RE:RE:RE:RE:Nice buying by ITG Canada today.

JD,

Your update is very much appreciated. Thanks.

BearDownAZ

JD wrote: "BearDownAZ, as I posted, the Sachs Forum conference went exceptionally well for biOasis. I talked with RH for an hour and a half yesterday. Gaba was great and our sessions were standing room only and they generated great interest amongst analysts, pharma execs and investors alike. About the website, discussion and planning are underway, have been for a while. I expect it to get done sooner than later. I'll make a call about the press release being absent from the website."

Bullboard Posts

Visionstate set to leverage success in the U.S. market